Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Megapharm Ltd.

Division of MegaPharm Ltd.
www.megapharm.co.il

Latest From Elan Pharmaceutical Technologies

Alkermes' Incrementalism

Alkermes' success in creating a commercial product out of Genentech's growth hormone has taken it across a fundamental credibility gap all new drug delivery companies face. One result: an extraordinarily high valuation that has permitted it to raise plenty of cash. And it's using these assets--credibility, cash and valuation--to invest in programs which can bring it nearer term revenues and higher margins, in terms of new, accelerated, or risk-sharing deals. Indeed, it's even treating its current net-loss position as an asset, spending heavily now--which its profitable competitors can't, given their valuation-sensitive earnings constraints--and even signing complex deals to take its partners' expenses onto its own P&L, reimbursing itself with equity and downstream milestones. Moreover, it's shown itself, as in its acquisition of Advanced Inhalation Research, willing to dramatically expand its portfolio of technologies with work done on the outside. Alkermes also wants to develop products for its own account, though its strategy for commercializing them, while maintaining a strong delivery technology base, is unclear.
BioPharmaceutical Business Strategies

Elan: The Virtues of the Middle

Big Pharma's growth problems are horrendous; biotech's a crapshoot. Much to everyone's surprise, mid-sized drug companies may have the most options. Having done four modest acquisitions since 1986, Elan has transformed itself and, in the process, shown how middle tier companies can take advantage of licensing and acquisition opportunities big companies can't touch.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • MegaPharm Ltd.
  • Senior Management
  • Miron Drucker, CEO
    Carni Gaoni, VP, COO
    Issy Peimer, Mgr., Bus. Dev.
    Hila Len, Mgr., Mktg.
  • Contact Info
  • Megapharm Ltd.
    Phone: (972) 9 7604596
    Hapnina Street 8, Building B
    1st Floor
    Raanana, 43215
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register